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INTRODUCTION
The discovery that various of the naturally occurring and synthetic analogues
of thyroxine possess some of the many physiological properties of thyroid
hormone in variable activity8"", 1416"1725," has stimulated a search for an
analogue with the cholesterol-lowering action of desiccated thyroid but with-
out toxic side effects. Such a compound has been sought to decrease the
serum cholesterol concentrations of patients with hypercholesterolemia and
vascular disease. Thyroxine itself lowers the serum cholesterol but the
effect is sustained only when the dosage is raised to concentrations which
may produce tachycardia, nervousness, palpitations, or weight loss.'2 Bauer,
McGavack, and Swell5 and Rawson, et al.,21 reported a reduction of serum
cholesterol in man without increase in basal metabolic rate by the adminis-
tration of 3, 5, 3'-triiodothyropropionic acid, an analogue of thyroxine re-
ferred to here as TRIPROP. Other lipid parameters were not measured, and
long-range studies have not been reported.
The present study was undertaken to determine the effect of TRIPROP$
on serum lipids when administered to normal persons in large doses for
a short period of time and when given for longer periods to patients with
elevated concentrations of serum lipids. The effect of TRIPROP on serum
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triglyceride concentration was of particular interest in relation to the in-
creased serum triglycerides in coronary artery disease.8" In short-term ex-
periments, large amounts of TRIPROP were given to obtain a maximal
effect of the drug on serum lipids, particularly on plasma-free fatty acids,
a fraction of plasma lipids which has been found to be important in mobi-
lization of fat from depots.7" In the long term experiments small initial
doses of TRIPROP were increased gradually to avoid possible toxic effects
to patients with overt or incipient coronary artery disease.
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FIG. 1. Plasma FFA of three subjects during a control day (left) and following the
administration of a single dose of 0.3 mg. per kg. bodywegiht of TRIPROP.
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METHODS
Acute experiments. (i) The effect of short-term administration of TRIPROP was
studied in medical students or hospital employees with an age span of 23 to 26 years.
All were free from known disease. The effect of a single large dose was assessed in
three normal persons. Measurements were made of the plasma FFA,',' total fatty
acids,2"'8 lipid phosphorus,'7 and total cholesterol1" at about 7:30 A.M. after an over-
night fast of approximately twelve hours. Samples were taken at 1, 2, 5¼/2, 8¼2, 12, and
TABLE 1. BEI CONCENTRAT'IONS IN PLASMA OF FOUR ADULTS AND ONE 9-MONTH-OLD BABY AT
INTERVALS FOLLOWING A SINGLE DOSE OF TRIPROP
BEI in Ag. per 100 ml. serum
Subject TRIPROP Before Hours after TRIPROP
Dosage TRIPROP Y2 1 2 4 5¼2 6 8X2 12 24 56 94 192
A.M. 0.15 mg./kg. 4.6* 6.6* 10.9* 9.8* 5.3 3.0
(17 mg.)
with 50 Gm.
glucose
is 0.15 mg./kg. 3.7 14.8 8.7 9.5 7.5 2.5 3.5 4.1
with regular
breakfast
(17 mg.)
V.M. 0.3 mg./kg. 3.8* 12.0* 19.1* 11.3* 11.3*
(24 mg.)
P.L. 0.3 mg./kg. 4.2* 16.7*
C.P. 3 mg. 4.7* 6.2* 5.9* 4.6
Pod. 4 mg. 3.0** 17.0 12.6 11.5
*Fasting (except for the glucose in the first experiment on A.M.).
**Average of three previous determinations.
24 hours for the analysis of the FFA, at 8¼2 and 24 hours for the lipid phosphorus,
total fatty acids, and cholesterol. Triglycerides were estimated by difference"l' and
were expressed as triglyceride fatty acids in milliequivalents per liter. At 5¼2, 8¼,2 and
24 hours, exhaled gas samples were obtained for determination of the respiratory
quotient and the basal metabolic rate."" Because of the method of gas collection,
any degree of hypoventilation or hyperventilation would give rise to a misrepresentation
of the actual amount of carbon dioxide produced and oxygen used by the body's over-
all metabolism. As a result of these uncontrollable factors, the results of the BMR and
respiratory quotient measurements in the present study cannot be accepted as unequi-
vocal. Throughout the 24 hours the subjects did not ingest any food but were allowed
to have water.
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One week later the same measurements were made as on the control day, but after
the initial collection of samples, TRIPROP in doses of 0.3 mg. per kilo body weight was
administered orally. In addition to the above measurements, at 0, 1, 5X,2, 8Y2, 12, and
24 hours in one subject and at 0 and 51,2 hours in another, blood samples were obtained
for the analysis of the serum butanol extractable iodine (BEI).
(ii) An independent study on the influence of a single dose of TRIPROP on the
concentration of the BEI was made on three normal subjects, on a patient with
coronary artery disease, and on a nine-month-old baby.
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FIGURE 2. Plasma cholesterol of four subjects during a control period and during
a five-day period of daily administration of 0.3 mg. TRIPROP per kg. body weight.
Medication was begun immediately after blood was drawn on experimental day one,
and given each subsequent day after the withdrawal of blood for lipid analysis.
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Chronic experimeitts. Six euthyroid patients with elevated concentrations of serum
cholesterol, triglycerides, or both, and one obese myxedematous patient were given
TRIPROP in doses varying from 1 to 18 mg. daily. The obese patient was on a
calorically restricted diet. The fat intake of the other patients was moderately re-
stricted and did not change throughout the period of study.
In vitro experiments. In order to interpret the BEI'sP in vitro recoveries from serum
of several analogues of thyroxine including TRIPROP were conducted. The theoretical
BEI was calculated from the known composition of the various compounds and the
previously determined BEI of the sera.
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FIG. 3. Plasma FFA of four subjects during a control period and during a five-day
period of daily administration of 0.3 mg. TRIPROP per kg. body weight. See legend
of Figure 2 for time of medication.
RESULTS
Acutte experintents. Since no definite or consistent changes in concentra-
tion of cholesterol, lipid phosphorus, triglycerides, or respiratory quotient
were observed during the 24 hours following the ingestion of a single large
dose of TRIPROP, such data are not presented. The FFA increased to the
same degree with fasting whether or not TRIPROP was given (Fig. 1).
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This dose of TRIPROP caused a marked increase in BEI within one to five
hours, following which the BEI gradually decreased to a point below the
pretreatment concentration within 56-94 hours (Table I). In subject A.M.,
a more rapid rise occurred when TRIPROP was administered with a regu-
lar meal than with a solution of glucose.
Daily administration of TRIPROP for six days caused a considerable
reduction of plasma cholesterol to a concentration varying between 62 and
82 per cent of the initial values (see Fig. 2). However, the plasma total
fatty acids, triglyceride fatty acids, lipid phosphorus, and cholesterol-phos-
pholipid ratios did not exhibit a sufficiently consistent response to the ad-
TABLE 2. EFFECT OF 0.3MG. TRIPROP PER KG. BODY WEIGHT PER DAY ON
PLASMA CONCENTRATIONS OF BEI IN AG. PER 100 ML.*
SUBJECT
Days of TRIPROP Ingestion E.L. M.W.
0 3.2 4.8
2 28.3
3 22.2
4 19.9
5 24.4
*A total of 19 mg. TRIPROP daily was given to E.L., and 14 mg. to M.W.
ministration of TRIPROP to permit presentations of data. The rise of
FFA was difficult to interpret because of the variability of this fraction dur-
ing the control period (Fig. 3). The BEI rose markedly during the six days
(Table 2). The basal metabolic rate was variable and open to errors men-
tioned in methods, but nevertheless it appeared to rise during the adminis-
tration of TRIPROP (Table 3).
TRIPROP did not exert any definite or consistent influence on either
systolic or diastolic blood pressure. The morning pulse rate, however,
showed an upward trend. After five daily doses of TRIPROP the various
pulse rates were from 14 to 26 beats per minute more than the initial values.
All four subjects lost weight on the six-day regimen. In two subjects, as
much of a reduction as seven pounds in five days was seen. Mild and tran-
sient headaches occurred during the six-day experiment in two subjects, in
one of whom the onset of cephalalagia coincided with the onset of menstrual
flow, and with temporary increase in perspiration in the other of the two
subjects. With these exceptions, TRIPROP in the large dosage given here
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did not seem to cause any symptoms of nervousness, jitteriness, irritability,
increase in appetite, palpitation, or diarrhea.
Chronic experiments. Table 4 summarizes the serum lipids and BEI's of
six euthyroid patients and one myxedematous patient given TRIPROP in
various doses. Of the euthyroid patients, four or five patients receiving one
or two miligrams of TRIPROP daily had no significant change in choles-
terol. The first patient in Table 4 voluntarily lost weight during this period.
A decrease in cholesterol happened to coincide with the weight loss as some-
times occurs temporarily. Serum cholesterol concentrations decreased in
TABLE 3. EFFECT ON BASAL METABOLIC RATE OF FOUR SUBJECTS GIVEN TRIPROP
IN DAILY DOSES OF 0.3 MG. PER KG. BoDy WEIGHT, FOR Six DAYS.
BASAL METABOLIC RATE-COMPARISON IN PERCENTAGE WITH STANDARD
VALUES FOR COMPARABLE AGE AND SEX.
Control Experimental
Day1 Day 2 Day 3 Day 1* Day 2 Day 3 Day 4 Day 5 Day 6
R.M. +2.36 -15.47 -3.45 -.0.54 +46.6 -19.79 -4.48 +11.27
W.R. +14.1 +4.9 +16.4 +3.30 +32.8 +13.03 +35.80 +18.01 +30.7
E.L. -34.88 -13.56 -3.04 -25.59 -8.62 +2.30 +1.00 +9.0 +8.4
M.W. +9.26 -3.26 - -2.36 +3.29 +13.4 +15.0 +21.6
Average -5.3 -9.4 +4.0 -6.5 +18.5 +2.4 +11.7 +15.0 +19.0
*Subjects began taking TRIPROP after collection of all specimens on day 1 of
experimental period.
three of five patients receiving three to four mg. daily (43-5741, A.L.,
K.T.) and in four of five patients given six to eight mg. daily. One patient,
C.M., who had responded minimally to lower doses, was given 9 to 12 mg.
TRIPROP. On this dose her cholesterol fluctuated about a slight but- in-
significantly lower concentration (93 per cent of the pretreatment concen-
tration). A dose of 9 mg. was selected as maintenance since she reported
that she felt jittery when receiving 12 mg.
The myxedematous patient, 4946-20, was treated with a starting dose of
4 mg. TRIPROP daily. The cholesterol dropped progressively from 453 to
a low of 204 mg. per 100 ml. when the dose was 12 milligrams, eight weeks
after starting therapy. Serum cholesterol increased somewhat despite further
increase in the dose of 18 mg. daily. Because of excessive perspiration, the
amount of drug administered was reduced to 12 mg. daily. After 18 months
of continuous medication at this dose, the cholesterol was 242 mg. per cent.
The response oftriglycerides was quite variable, with no consistent trend,
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as indicated in Table 4. Only one of the seven patients, C.M., showed a
decrease in the cholesterol-phospholipid ratio while receiving TRIPROP.
In general, BEI's of the euthyroid patients were in the normal range of
3.3 to 6.4 micrograms per 160 ml. both before and during treatment. Excep-
tions were the slightly low BEI's before treatment in two patients (A.L.
and C.M.); however, at other times these patients had normal BEI's while
not receiving medication. There was a tendency for the BEI's to be lower
TABLE 5. SERUM BEI AND LIPIDS AT INTERVALS DURING THE DAY IN A
PATIENT TAKING A DAILY DOSE OF 5 MG. TRIPROP AT BREAKFAST
AND 4 MG. AT LUNCH. LAST COLUMN SHOWS STUDY MADE
48 HOURS AFTER LAST MEDICATION
9 a.m. 11 a.m. 2 p.m.
No TRIPROP 2 hrs. after 2 hrs. after 48 hrs.
after 5 mg. 4 mg. after last
_presiousnoon TRIPROP TRIPROP TRIPROP
BEI,
sg./100 ml. 3.8 10.5 13.6 1.4
Cholesterol,
mg./100 ml. 614 609 633 822
Triglyceride
fatty acids, 4.0 8.5 5.2 7.4
mEq./L.
Cholesterol:
phospholipid 1.40 1.26 1.35 1.60
ratio
than the pretreatment values when the patients were receiving small doses
(Table 4) and to be in the upper range of normal, up to 6 pg. per 100 ml.,
on higher doses. It should be noted that BEI's were determined at least 12
hours after the last medication. Considerably higher values occurred shortly
after intake of TRIPROP, as shown in Table 5. This table shows a normal
BEI in the morning when no TRIPROP had been administered for 21
hours, but it shows a high value later in the day, a few hours after the
patient had taken her TRIPROP. Forty-eight hours after temporary with-
drawal of the drug, the BEI was in thehypothyroid range and the cholesterol
had risen to the highest value ever recorded for this patient. She felt rather
tired and let down at this time.
All patients lost weight on effective and sometimes on ineffective doses
(Table 4). Patients rarely had resting pulse rates greater than 80 beats; per
444
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minute, and none displayed a rise in blood pressure while receiving the drug.
Increased perspiration, jitteriness, and easy fatigability were infrequent
complaints and noted only during the administration of doses of 6 mg. or
greater. Occasionally, faint pruritic rashes were observed but disappeared
during the continued treatment. For the most part, there were no subjective
symptoms.
TABLE 6. RECOVERY OF VARIOUS ANALOGUES OF THYROXINE AS BEI
FROM SERA TO WHICH ANALOGUES WERE ADDED
IN KNOWN AMOUNTS*
Theoretical BEI
(Serum BEI
Serum plusiodine added Iodinerecovered
Analogue BEI in thisanalogue) asBEI
microgramsper
micrograms per100ml. 100 ml.
Tetraiodothyropropionic
Acid 4.5 7.3 8.0
Triiodothyroacetic
Acid 3.3 9.4 9.3
Tetraiodothyroacetic
Acid 3.7 9.9 9.9
Triiodothyropropionic
Acid 3.2 9.8 9.4
Triiodothyronine 3.9 7.9 8.0
* Analogues were supplied by the Warner-Chilcott Laboratories Division. The solu-
tion of analogue in serum was of such concentration that half of 1 ml. of analogue
solution was added to portions of serum varying in quantity from 4 to 8 ml.
In addition, solutions of each of the analogues above except triiodothyronine were
subjected to total iodine analysis. Recoveries agreed within 100 to 107 per cent of
the calculated total iodine content.
In addition to the seven patients listed in Table 4, three obese patients
given TRIPROP with the purpose of inducing weight loss did not display
any weight-reducing effect from as much as 18 mg. daily. It was necessary
for them to restrict calories in the same manner as obese patients not re-
ceiving the drug.
In an isolated study not included in the tables, TRIPROP was given
for three days in doses of 4 mg. daily to a 28-year-old euthyroid female
patient with an enlarged thyroid. Such intake of TRIPROP decreased the
uptake of a tracer dose of radioactive iodine from the upper normal range
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to a borderline low range, and produced an increase in the BEI from 6.1
to 9.0 ,ug. per 100 ml. With continuation of the drug, size of the thyroid
gland decreased definitely.
In vitro studies. Recoveries of tetraiodothyropropionic acid, triiodothy-
roacetic acid, tetraiodothyroacetic acid, triiodothyropropionic acid, and tri-
iodothyronine added in vitro to serum were virtually complete (Table 6).
DISCUSSION
The striking reduction of plasma cholesterol following the administration
of TRIPROP in the six-day experiment indicates that TRIPROP pos-
sesses the cholesterol-lowering action of desiccated thyroid.' Bauer, Mc-
Gavack, and Swell, in a recent paper, reported that the administration of
TRIPROP in a dose of 6 mg. daily to euthyroid adults caused an average
reduction in serum cholesterol of 25 per cent after a period of two to four
weeks.' However, in the present investigations (Fig. 2), a dosage of
TRIPROP much larger than that used by Bauer, et al. was adopted and
correspondingly, the response was observed much sooner. The brevity of
the acute experiment prevents prediction of the response of serum cholesterol
to a more prolonged treatment with TRIPROP at the constant dose of 0.3
mg. per kilo of body weight.
The long-term administration of TRIPROP to patients with initially
elevated serum lipids resulted in a small reduction in concentration of
cholesterol when administered in doses varying from 3 to 9 mg. daily. The
effectiveness of the drug appeared to depend on a time-dose relationship.
If a dose sufficiently great to lower the cholesterol was achieved within four
months of initiation of TRIPROP, the cholesterol decreased more than 15
per cent. If an effective dose was reached after six months or longer of
gradually increasing small doses, the cholesterol was reduced by less than
10 per cent. The only instance of a marked and sustained reduction in con-
centration of cholesterol was for the myxedematous patient in whom
TRIPROP, in doses from 9 to 18 mg. daily, appeared as adequate as desic-
cated thyroid in the treatment of hypothyroidism. Possibly smaller doses
would have served as well' but large doses were given to encourage weight
loss.
Although this series is small, a comparison of the acute experiments, not
only with short term experiments of others but also with the long term
evaluation of TRIPROP, is compatible with an escape of the cholesterol-
lowering effect of TRIPROP administered to euthyroid persons. Such es-
cape might be expected from the infrequency with which low serum choles-
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terol concentrations are found in naturally hyperthroid persons although the
reverse finding of high cholesterol in hypothyroidism is the rule.'
Escape of the cholesterol-lowering effect of TRIPROP may be accounted
for in part by suppression of endogenous thyroid function occurring early
after administration of the drug. This suppression was manifest in a single
instance by a marked decrease in I' uptake in a patient after three days
of receiving TRIPROP; in normal subjects, by a decline in concentration
of BEI below pretreatment values three to four days after a single large
dose (Table 2); and, despite the continued administration of TRIPROP
in large doses (Table 2), by a decrease of the fourth day BEI after an in-
itial rise. Additional evidence for the suppression of endogenous thyroid
function was the tendency for BEI's to be low in patients receiving small
doses of TRIPROP (Table 4). A similar phenomenon occurred to a more
marked degree in one patient who temporarily stopped the drug and who
48 hours later had a BEI in the hypothyroid range and a marked elevation
of her cholesterol (Table 5).
The PBI but not the BEI was greatly elevated during administration of
TRIPROP. One patient, 49-46-20 (Table 4) had a serum PBIU of 22 ,ug.
per 100 ml. on two occasions when the BEI was in the normal range and the
patient was clinically euthyroid. PBI's in a similar range and also out of
proportion to the clinical response were reported by Hill, et al.'8 in patients
receiving TRIPROP and tetraiodothyropropionic acid. BEI's during such
treatment have not previously been reported. The complete recovery of
TRIPROP added to serum in vitro (Table 6) excludes the possibility that
incomplete recovery of TRIPROP accounted for the discrepancy between
BEI and PBI.
Weight loss was noted in all subjects of the acute and long-term experi-
ments. No consistent changes in diet were reported by any of the patients,
although in studies of outpatients exact caloric intake is difficult to judge.
The well-known increase in basal metabolic rate characteristic of the hyper-
thyroid state could, if induced byadministration of TRIPROP, cause weight
loss. The present study shows a suggestive increase in the BMR following
the acute administration of TRIPROP but variability of the parameter pre-
vents firm conclusion. At the doses given, it is possible that TRIPROP
caused weight loss by increasing the basal metabolic rate. Others have
reported a calorigenic effect of TRIPROP and have also found that the
cholesterol-lowering effect of TRIPROP occurs at lower doses than the
calorigenic effect in myxedematous and euthyroid patients.5"8321 At the doses
used in the present study the cholesterol-lowering and weight-reducing
action of TRIPROP appeared to coincide. Indeed, with prolonged adminis-
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tration, its effect on weight was manifest at a time when the cholesterol
effect was minimal.
Rich, Bierman, and Schwartz' have recently demonstrated that the hyper-
thyroid state, whether as a result of hyperthyroidism or as a consequence of
administration of triiodothyronine, is accompanied by a rise in the concen-
tration of plasma FFA. The rise in plasma FFA was thought to signify
mobilization of fat as FFA from adipose tissue. The present experiments,
however, show only suggestive increases in the values of FFA following ad-
ministration of TRIPROP in doses as large as 0.3 mg./kg. of body weight.
The lack of a clear-cut effect of thyroid-like hormones on FFA could be
explained by two of its opposing actions as proposed by Hagen.' Thyroid
hormone increases the sensitivity of adipose tissue to insulin, causing an
increased utilization of glucose with resulting suppression of FFA release.
At the same time thyroid hormone exerts a direct fat-mobilizing effect on
adipose tissue with an increase of FFA release. A balance of these two
actions could result in no over-all change in FFA concentration.
The evidence presented here is compatible with the thesis that TRIPROP
has some of the physiological properties of thyroid to a greater extent
than others. Both the cholesterol-lowering and weight-reducing effects of
TRIPROP appear to be similar to those of desiccated thyroid. However,
the cardiovascular effects of thyroxine were notably absent.
Twoofthe fourpatients with previous myocardial infarctions had episodes
of myocardial insufficiency while receiving the drug, although the attacks
could well have been the result of the disease and not of the drug. Two
patients with tendinous and skin xanthomata exhibited progression of
their lesions during two years of therapy with the drug, perhaps because
effective dosage with regard to its effect on the cholesterol concentration was
not maintained during all of this period.
With respect to cholesterol concentrations, the dramatic reduction in the
acute experiments was not sustained with prolonged use of the drug. Serum
triglycerides, which may be of greater significance than cholesterol in
coronary artery disease,8" were not consistently influenced by TRIPROP
administration. This accords with the smaller response of low density
lipoproteins, the main source of plasma triglycerides, rather than the re-
sponse of cholesterol to the administration of thyroid hormone, and it is in
accord with the usually normal concentration of triglycerides in the sera
of hypercholesterolemic hypothyroid patients.'9 The possible therapeutic
usefullness of TRIPROP in creating and maintaining an altered in vivo
lipid environment cannot be determined on the basis of the present study.
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SUMMARY
1. The effect of 3,5,3' triiodothyropropionic acid (TRIPROP) on plasma
lipids was studied by the administration of this substance to seven normal
subjects in a short-term experiment, to six euthyroid patients with elevated
lipid concentrations in a long-term study, and to one myxedematous patient.
Serum or plasma was analyzed for BEI, cholesterol, FFA, total fatty acids,
triglyceride fatty acids, and phospholipids.
2. No consistent effects of TRIPROP on plasma FFA, triglyceride fatty
acids, phospholipids, cholesterol, and basal metabolic rate were observed
within 24 hours of a single large dose although a marked increase in plasma
BEI took place within one to five hours. However, five days of adminis-
tration of 0.3 mg. per kg. body weight caused a marked decrease in serum
cholesterol concentration varying from 18 to 38 per cent. The changes in
FFA were equivocal, and the other lipid components did not change. Weight
loss occurred in all subjects. The subjective symptoms of thyroid over-
activity such as tachycardia, palpitations, and nervousness were absent.
3. The administration of 3 mg. or more of TRIPROP daily to six euthy-
roid patients with high blood lipids caused a small reduction of serum choles-
terol. The decrease was greater than 15 per cent during the first four to six
months of treatment only, and was less than 10 per cent with prolonged ad-
ministration. No consistent effect on triglyceride concentration or the choles-
terol-phospholipid ratio was noted. Weight loss occurred in all patients
given doses sufficient to lower the cholesterol. Subjective symptoms were
absent or minimal.
4. Marked and permanent reduction of all lipid components of serum
and restoration of the euthyroid state followed administration of TRIPROP
to one myxedematous patient.
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